This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Don Dion's Weekly ETF Blog Wrap

Stocks in this article: IHE ESR GUR

Here is some of what Don Dion blogged about on RealMoney this past week.

Two Ways to Play a Rise in Pharma

Posted 12/03/2009 2:45 p.m. EST

Health care reform is withering in the Senate, and other matters have distracted the president. The pharmaceutical sector is poised to benefit.

With Obama focusing on the current economic situation and the war in Afghanistan, there is a good chance that the health care reform bill will stall. With lawmakers distracted, this is a prime time for investors looking for exposure to the health care sector to jump in. However, when deciding which fund to include in your portfolio, numerous options are available.

In the case of pharmaceuticals, two particularly strong options are the iShares Dow Jones U.S. Pharmaceuticals Index Fund (IHE) and the SPDR S&P Pharmaceuticals ETF (XPH). Both instruments provide investors with direct access to some of the most dominant drug companies around. Their differences, however, have caused them to vary in performance.

Year to date for the period ending Dec. 2, IHE has gained nearly 30%, while XPH has jumped 24%.

Because a small number of big-name firms dominate the pharmaceutical arena, both funds hold many identical firms in their top holdings. Some names include Merck (MRK), Pfizer (PFE), Eli Lilly (LLY) and Abbott Laboratories (ABT). The top 10 holdings of XPH represent close to 50% of the fund's total portfolio. For IHE, the largest weighted firms make up over 60%.

While IHE appears more heavily weighted looking its top firms, in total, the fund has 31 total holdings; XPH has 22.

XPH gains a leg up, however, when it comes to fees. Investors holding IHE face a 0.48% expense ratio vs. XPH's 0.36%.

When it comes down to it, although XPH is cheaper and is less top-heavy than IHE, it's the performance that matters. While both funds will likely perform well as health care reform flounders, I would advise investors to stick to IHE for the best play on the pharmaceutical industry.

>>Bull or Bear? Vote in Our Poll

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs